Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Indaptus is a clinical-stage biotechnology company developing Decoy20, a novel, multi-targeted immunotherapy for unresectable or metastatic solid tumors and lymphomas. The company is currently conducting a Phase 1 clinical trial and has initiated a Phase 1 combination study with Tislelizumab.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,532,430) | $(3,806,677) |
| Loss Per Share (Basic & Diluted) | $(0.32) | $(0.45) |
| Cash and Cash Equivalents (End of Period) | $3,891,021 | $9,741,638 |
| Net Cash Used in Operating Activities | $(5,047,127) | $(3,936,462) |
| Net Cash Provided by Financing Activities | $3,151,395 | $316,047 |
| Total Assets | $5,411,622 | $7,338,756 |
| Accumulated Deficit | $(64,971,613) | $(49,223,833) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 16.0% to $4.57 million.
- R&D Expenses: Increased 76.7% to $2.81 million, driven primarily by a $1.5 million increase in costs associated with the Phase 1 clinical trial.
- G&A Expenses: Decreased 25.1% to $1.76 million, attributed to reductions in payroll and legal fees.
- Liquidity: Cash and cash equivalents decreased by approximately $1.9 million during the quarter due to operating cash burn, partially offset by financing activities.
- Capitalization: The company raised approximately $3.2 million in net proceeds during Q1 2025 through a private placement (January) and sales under a Standby Equity Purchase Agreement (SEPA) (March).
Outlook, Risks, and Management Commentary
Going Concern Warning
Management has identified conditions that raise substantial doubt regarding the company's ability to continue as a going concern. Based on the current operating plan, the company expects to require additional capital to fund operations beyond the second quarter of 2025.
Strategic Initiatives
- Clinical Progress: Enrollment in the weekly dosing portion of the Phase 1 monotherapy trial has concluded. The company is now focusing on the Phase 1 Combination Study of Decoy20 with Tislelizumab, initiated in March 2025.
- Cost Reduction: In May 2025, the company began implementing a cost-reduction plan, including voluntary temporary salary reductions for certain officers and the temporary elimination of board fees.
- Financing: The company entered into a SEPA in February 2025, allowing for the sale of up to $20.0 million of common stock over 36 months. As of March 31, 2025, $1.15 million in net proceeds had been generated under this agreement.
Risk Factors
- Dependence on successful clinical trial outcomes and regulatory approval.
- Need for additional capital; failure to secure financing could force delays or cessation of operations.
- Potential dilution to existing shareholders from future equity raises.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.89 million cash balance against the stated need for capital beyond Q2 2025.
- Financing Terms: Review the specific terms of the SEPA with Yorkville and the private placement warrants, including exercise prices and dilution impact.
- Clinical Milestones: Monitor the initiation and early safety data of the Decoy20/Tislelizumab Combination Study.
- Cost Cutting Efficacy: Assess the impact of the May 2025 cost-reduction plan on future quarterly burn rates.
- Going Concern Status: Confirm if the company has secured additional funding or partnerships to resolve the substantial doubt regarding its ability to continue operations.